{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T07:30:00Z","timestamp":1792740600385,"version":"4.5.0"},"reference-count":37,"publisher":"Elsevier BV","issue":"32","license":[{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1016\/j.vaccine.2022.05.016","type":"journal-article","created":{"date-parts":[[2022,6,29]],"date-time":"2022-06-29T07:55:33Z","timestamp":1656489333000},"page":"4283-4291","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Methodology for a correlate of protection for group B Streptococcus: Report from the Bill &amp; Melinda Gates Foundation workshop held on 10 and 11 February 2021"],"prefix":"10.1016","volume":"40","author":[{"given":"Peter B.","family":"Gilbert","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Isbrucker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nick","family":"Andrews","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Goldblatt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul T.","family":"Heath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alane","family":"Izu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shabir A.","family":"Madhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawrence","family":"Moulton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie J.","family":"Schrag","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nong","family":"Shang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Siber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajoke","family":"Sobanjo-ter Meulen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2022.05.016_b0005","unstructured":"World Health Organization. Newborns: improving survival and well-being. 2020."},{"issue":"1","key":"10.1016\/j.vaccine.2022.05.016_b0010","doi-asserted-by":"crossref","first-page":"e0191193","DOI":"10.1371\/journal.pone.0191193","article-title":"Invasive bacterial disease trends and characterization of group B streptococcal isolates among young infants in southern Mozambique, 2001\u20132015","volume":"13","author":"Siga\u00faque","year":"2018","journal-title":"PLoS ONE"},{"issue":"11","key":"10.1016\/j.vaccine.2022.05.016_b0015","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1097\/INF.0b013e318223bad2","article-title":"The burden of invasive early-onset neonatal sepsis in the United States, 2005\u20132008","volume":"30","author":"Weston","year":"2011","journal-title":"Pediatr Infect Dis J"},{"issue":"suppl_2","key":"10.1016\/j.vaccine.2022.05.016_b0020","doi-asserted-by":"crossref","first-page":"S100","DOI":"10.1093\/cid\/cix658","article-title":"Maternal Colonization With Group B Streptococcus and Serotype Distribution Worldwide: Systematic Review and Meta-analyses","volume":"65","author":"Russell","year":"2017","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2022.05.016_b0025","unstructured":"Centers for Disease Control and Prevention. Active Bacterial Core Surveillance (ABCs). 2021."},{"issue":"1","key":"10.1016\/j.vaccine.2022.05.016_b0030","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/S1473-3099(18)30555-3","article-title":"Group B streptococcal disease in UK and Irish infants younger than 90 days, 2014\u201315: a prospective surveillance study","volume":"19","author":"O'Sullivan","year":"2019","journal-title":"Lancet Infect Dis"},{"issue":"2","key":"10.1016\/j.vaccine.2022.05.016_b0035","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/S1473-3099(20)30478-3","article-title":"Safety and immunogenicity of a novel hexavalent group B streptococcus conjugate vaccine in healthy, non-pregnant adults: a phase 1\/2, randomised, placebo-controlled, observer-blinded, dose-escalation trial","volume":"21","author":"Absalon","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2022.05.016_b0040","doi-asserted-by":"crossref","first-page":"D52","DOI":"10.1016\/j.vaccine.2013.02.029","article-title":"Considerations for a phase-III trial to evaluate a group B Streptococcus polysaccharide-protein conjugate vaccine in pregnant women for the prevention of early- and late-onset invasive disease in young-infants","volume":"31","author":"Madhi","year":"2013","journal-title":"Vaccine"},{"issue":"5","key":"10.1016\/j.vaccine.2022.05.016_b0045","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1093\/infdis\/jit549","article-title":"Maternal antibody at delivery protects neonates from early onset group B streptococcal disease","volume":"209","author":"Baker","year":"2014","journal-title":"J Infect Dis"},{"issue":"48","key":"10.1016\/j.vaccine.2022.05.016_b0050","doi-asserted-by":"crossref","first-page":"6793","DOI":"10.1016\/j.vaccine.2015.10.019","article-title":"Correlates of protection of serotype-specific capsular antibody and invasive Group B Streptococcus disease in South African infants","volume":"33","author":"Dangor","year":"2015","journal-title":"Vaccine"},{"issue":"24","key":"10.1016\/j.vaccine.2022.05.016_b0055","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1056\/NEJM198406143102404","article-title":"Prevention of Hemophilus influenzae type b bacteremic infections with the capsular polysaccharide vaccine","volume":"310","author":"Peltola","year":"1984","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.vaccine.2022.05.016_b0060","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1093\/infdis\/147.6.1100","article-title":"The protective level of serum antibodies to the capsular polysaccharide of Haemophilus influenzae type b","volume":"147","author":"Kayhty","year":"1983","journal-title":"J Infect Dis"},{"issue":"6","key":"10.1016\/j.vaccine.2022.05.016_b0065","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1093\/infdis\/149.6.1034","article-title":"The protective level of serum antibodies to the capsular polysaccharide of Haemophilus influenzae type b","volume":"149","author":"Anderson","year":"1984","journal-title":"J Infect Dis"},{"issue":"20","key":"10.1016\/j.vaccine.2022.05.016_b0070","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1056\/NEJM199011153232004","article-title":"A randomized, prospective field trial of a conjugate vaccine in the protection of infants and young children against invasive Haemophilus influenzae type b disease","volume":"323","author":"Eskola","year":"1990","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2022.05.016_b0075","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1084\/jem.129.6.1327","article-title":"Human immunity to the meningococcus. II. Development of natural immunity","volume":"129","author":"Goldschneider","year":"1969","journal-title":"J Exp Med"},{"issue":"5","key":"10.1016\/j.vaccine.2022.05.016_b0080","first-page":"780","article-title":"Validation of serological correlate of protection for meningococcal C conjugate vaccine by using efficacy estimates from postlicensure surveillance in England","volume":"10","author":"Andrews","year":"2003","journal-title":"Clin Diagn Lab Immunol"},{"issue":"3","key":"10.1016\/j.vaccine.2022.05.016_b0085","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1128\/IAI.69.3.1568-1573.2001","article-title":"Serological basis for use of meningococcal serogroup C conjugate vaccines in the United Kingdom: reevaluation of correlates of protection","volume":"69","author":"Burns","year":"2001","journal-title":"Infect Immun"},{"issue":"3","key":"10.1016\/j.vaccine.2022.05.016_b0090","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1097\/00006454-200003000-00003","article-title":"Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group","volume":"19","author":"Black","year":"2000","journal-title":"Pediatr Infect Dis J"},{"issue":"19","key":"10.1016\/j.vaccine.2022.05.016_b0095","doi-asserted-by":"crossref","first-page":"3816","DOI":"10.1016\/j.vaccine.2007.01.119","article-title":"Estimating the protective concentration of anti-pneumococcal capsular polysaccharide antibodies","volume":"25","author":"Siber","year":"2007","journal-title":"Vaccine"},{"issue":"23","key":"10.1016\/j.vaccine.2022.05.016_b0100","doi-asserted-by":"crossref","first-page":"3265","DOI":"10.1016\/S0264-410X(03)00230-5","article-title":"Serological criteria for evaluation and licensure of new pneumococcal conjugate vaccine formulations for use in infants","volume":"21","author":"J\u00f3dar","year":"2003","journal-title":"Vaccine"},{"issue":"9","key":"10.1016\/j.vaccine.2022.05.016_b0105","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S1473-3099(14)70822-9","article-title":"Serotype-specific effectiveness and correlates of protection for the 13-valent pneumococcal conjugate vaccine: a postlicensure indirect cohort study","volume":"14","author":"Andrews","year":"2014","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2022.05.016_b0110","unstructured":"U.S. Department of Health and Human Services FaDA. Guidance for Industry: Expedited Programs for Serious Conditions \u2013 Drugs and Biologics. 2014."},{"key":"10.1016\/j.vaccine.2022.05.016_b0115","unstructured":"US Food and Drug Administration (FDA). Vaccines and Related Biological Products Advisory Committee May 17, 2018 Meeting Announcement May 17 2018. 2018."},{"issue":"24","key":"10.1016\/j.vaccine.2022.05.016_b0120","doi-asserted-by":"crossref","first-page":"3190","DOI":"10.1016\/j.vaccine.2019.04.039","article-title":"The role of immune correlates of protection on the pathway to licensure, policy decision and use of group B Streptococcus vaccines for maternal immunization: considerations from World Health Organization consultations","volume":"37","author":"Vekemans","year":"2019","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2022.05.016_b0125","unstructured":"US Food and Drug Administration (FDA). Framework for FDA\u2019s Real-World Evidence Program. 2018."},{"issue":"9","key":"10.1016\/j.vaccine.2022.05.016_b0130","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1002\/sim.2282","article-title":"A model for immunological correlates of protection","volume":"25","author":"Dunning","year":"2006","journal-title":"Stat Med"},{"issue":"5","key":"10.1016\/j.vaccine.2022.05.016_b0135","doi-asserted-by":"crossref","first-page":"e1170","DOI":"10.1093\/cid\/ciaa1873","article-title":"Association of Group B Streptococcus (GBS) Serum Serotype-Specific Anticapsular Immunoglobulin G Concentration and Risk Reduction for Invasive GBS Disease in South African Infants: An Observational Birth-Cohort","volume":"73","author":"Madhi","year":"2021","journal-title":"Matched Case-Control Study Clin Infect Dis"},{"issue":"6","key":"10.1016\/j.vaccine.2022.05.016_b0140","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1093\/cid\/ciw377","article-title":"The Protective Value of Maternal Group B Streptococcus Antibodies: Quantitative and Functional Analysis of Naturally Acquired Responses to Capsular Polysaccharides and Pilus Proteins in European Maternal Sera","volume":"63","author":"Fabbrini","year":"2016","journal-title":"Clin Infect Dis"},{"issue":"1","key":"10.1016\/j.vaccine.2022.05.016_b0145","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1111\/j.0006-341X.2001.00135.x","article-title":"Bayesian inference on protective antibody levels using case-control data","volume":"57","author":"Carey","year":"2001","journal-title":"Biometrics"},{"key":"10.1016\/j.vaccine.2022.05.016_b0150","doi-asserted-by":"crossref","first-page":"2973","DOI":"10.1002\/sim.5403","article-title":"Biomarkers and surrogate endpoints in clinical trials","volume":"31","author":"Fleming","year":"2012","journal-title":"Stat Med"},{"key":"10.1016\/j.vaccine.2022.05.016_b0155","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1214\/18-AOAS1237","article-title":"Nonparametric inference for immune response thresholds of risk in vaccine studies","volume":"13","author":"Donovan","year":"2019","journal-title":"Ann Appl Stat"},{"key":"10.1016\/j.vaccine.2022.05.016_b0160","unstructured":"van der Laan L ZW, Gilbert PB. Efficient nonparametric estimation of the covariate-adjusted threshold-response function and thresholds of protection. arXiv:210711459 2021."},{"key":"10.1016\/j.vaccine.2022.05.016_b0165","doi-asserted-by":"crossref","first-page":"108577","DOI":"10.1016\/j.spl.2019.108577","article-title":"On doubly robust estimation for logistic partially linear models","volume":"155","author":"Tan","year":"2019","journal-title":"Statistics & Probability Letters"},{"key":"10.1016\/j.vaccine.2022.05.016_b0170","first-page":"Article 1","article-title":"Why match? Investigating matched case-control study designs with causal effect estimation","volume":"5","author":"Rose","year":"2009","journal-title":"Int J Biostat"},{"key":"10.1016\/j.vaccine.2022.05.016_b0175","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1002\/sim.3811","article-title":"Estimators and confidence intervals for the marginal odds ratio using logistic regression and propensity score stratification","volume":"29","author":"Stampf","year":"2010","journal-title":"Stat Med"},{"issue":"5","key":"10.1016\/j.vaccine.2022.05.016_b0180","doi-asserted-by":"crossref","first-page":"e162","DOI":"10.1016\/S1473-3099(18)30659-5","article-title":"Serocorrelates of protection against infant group B streptococcus disease","volume":"19","author":"Le Doare","year":"2019","journal-title":"Lancet Infect Dis"},{"issue":"4","key":"10.1016\/j.vaccine.2022.05.016_b0185","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1093\/ije\/dys223","article-title":"Why representativeness should be avoided","volume":"42","author":"Rothman","year":"2013","journal-title":"Int J Epidemiol"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X22005874?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X22005874?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T11:13:35Z","timestamp":1759403615000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X22005874"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7]]},"references-count":37,"journal-issue":{"issue":"32","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["S0264410X22005874"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2022.05.016","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Methodology for a correlate of protection for group B Streptococcus: Report from the Bill & Melinda Gates Foundation workshop held on 10 and 11 February 2021","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2022.05.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"name":"copyright","label":"Copyright"}]}}